Healthcare provider profile · identity verified

Gina Rocillo, MD

Family Practice · BUENA PARK, CA · NPI 1811145113

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	324	100
Losartan Potassium	Losartan Potassium	276	80
Amlodipine Besylate	Amlodipine Besylate	259	78
Levothyroxine Sodium	Levothyroxine Sodium	153	45
Rosuvastatin Calcium	Rosuvastatin Calcium	151	51
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	126	23
Gabapentin	Gabapentin	119	30
Metformin Hcl	Metformin Hcl	113	36
Alendronate Sodium	Alendronate Sodium	103	35
Omeprazole	Omeprazole	103	32
Lisinopril	Lisinopril	102	34
Furosemide	Furosemide	89	29
Pioglitazone Hcl	Pioglitazone Hcl	89	29
Albuterol Sulfate Hfa	Albuterol Sulfate	87	28
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	86	27
Jardiance	Empagliflozin	81	20
Ozempic	Semaglutide	76	16
Ibuprofen	Ibuprofen	73	18
Trazodone Hcl	Trazodone Hcl	67	16
Azithromycin	Azithromycin	66	47
Hydralazine Hcl	Hydralazine Hcl	66	20
Lorazepam	Lorazepam	64	11
Tramadol Hcl	Tramadol Hcl	64	26
Montelukast Sodium	Montelukast Sodium	63	18
Simvastatin	Simvastatin	63	22
Tamsulosin Hcl	Tamsulosin Hcl	63	20
Metoprolol Succinate	Metoprolol Succinate	62	19
Pantoprazole Sodium	Pantoprazole Sodium	61	28
Pravastatin Sodium	Pravastatin Sodium	59	19
Atenolol	Atenolol	57	21
Hydrochlorothiazide	Hydrochlorothiazide	57	17
Trulicity	Dulaglutide	56	12
Vitamin D2	Ergocalciferol (Vitamin D2)	51	17
Diclofenac Sodium	Diclofenac Sodium	50	15
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	49	37
Eliquis	Apixaban	47	12
Escitalopram Oxalate	Escitalopram Oxalate	46	14
Zolpidem Tartrate	Zolpidem Tartrate	46	suppressed
Clonazepam	Clonazepam	45	suppressed
Famotidine	Famotidine	43	16
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	42	suppressed
Alprazolam	Alprazolam	41	suppressed
Allopurinol	Allopurinol	39	14
Fluticasone Propionate	Fluticasone Propionate	39	18
Triamcinolone Acetonide	Triamcinolone Acetonide	39	20
Carvedilol	Carvedilol	35	11
Meclizine Hcl	Meclizine Hcl	34	16
Metformin Hcl Er	Metformin Hcl	34	12
Metoprolol Tartrate	Metoprolol Tartrate	32	11
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	31	15
Januvia	Sitagliptin Phosphate	30	suppressed
Chlorthalidone	Chlorthalidone	29	suppressed
Benazepril Hcl	Benazepril Hcl	27	suppressed
Ezetimibe	Ezetimibe	27	suppressed
Meloxicam	Meloxicam	27	13
Ondansetron Hcl	Ondansetron Hcl	27	suppressed
Potassium Chloride	Potassium Chloride	27	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	26	suppressed
Mirtazapine	Mirtazapine	26	suppressed
Lansoprazole	Lansoprazole	25	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	24	suppressed
Baclofen	Baclofen	24	suppressed
Donepezil Hcl	Donepezil Hcl	24	suppressed
Farxiga	Dapagliflozin Propanediol	24	suppressed
Glipizide	Glipizide	24	suppressed
Metronidazole	Metronidazole	24	suppressed
Pregabalin	Pregabalin	24	suppressed
Tizanidine Hcl	Tizanidine Hcl	24	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	23	16
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	23	16
Ibandronate Sodium	Ibandronate Sodium	22	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	22	suppressed
Spironolactone	Spironolactone	22	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	22	16
Pioglitazone-Metformin	Pioglitazone Hcl/Metformin Hcl	21	suppressed
Carisoprodol	Carisoprodol	20	suppressed
Duloxetine Hcl	Duloxetine Hcl	20	suppressed
Finasteride	Finasteride	20	suppressed
Hydrocortisone	Hydrocortisone	20	suppressed
Janumet Xr	Sitagliptin Phos/Metformin Hcl	20	suppressed
Lovastatin	Lovastatin	20	suppressed
Nystatin	Nystatin	20	12
Quetiapine Fumarate	Quetiapine Fumarate	20	suppressed
Temazepam	Temazepam	20	suppressed
Tradjenta	Linagliptin	20	suppressed
Cefuroxime	Cefuroxime Axetil	18	14
Cephalexin	Cephalexin	18	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	18	suppressed
Xarelto	Rivaroxaban	18	suppressed
Clopidogrel	Clopidogrel Bisulfate	16	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	16	suppressed
Xigduo Xr	Dapaglifloz Propaned/Metformin	16	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	15	suppressed
Clonidine Hcl	Clonidine Hcl	15	suppressed
Linzess	Linaclotide	15	suppressed
Mometasone Furoate	Mometasone Furoate	15	suppressed
Prednisone	Prednisone	15	11
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	15	suppressed
Citalopram Hbr	Citalopram Hydrobromide	14	suppressed
Labetalol Hcl	Labetalol Hcl	14	suppressed
Lidocaine	Lidocaine	14	suppressed
Gemfibrozil	Gemfibrozil	13	suppressed
Glipizide Er	Glipizide	13	suppressed
Memantine Hcl	Memantine Hcl	13	suppressed
Azelastine Hcl	Azelastine Hcl	12	suppressed
Carbamazepine	Carbamazepine	12	suppressed
Clobetasol Propionate	Clobetasol Propionate	12	suppressed
Estradiol	Estradiol	12	suppressed
Mounjaro	Tirzepatide	12	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	12	suppressed
Synjardy Xr	Empagliflozin/Metformin Hcl	12	suppressed
Amiodarone Hcl	Amiodarone Hcl	11	suppressed
Entresto	Sacubitril/Valsartan	11	suppressed
Flunisolide	Flunisolide	11	suppressed
Mupirocin	Mupirocin	11	suppressed
Nebivolol Hcl	Nebivolol Hcl	11	suppressed
Neomycin-Polymyxin-Hc	Neomycin/Polymyxin B/Hydrocort	11	11
Olmesartan Medoxomil	Olmesartan Medoxomil	11	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	11	suppressed
Telmisartan	Telmisartan	11	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	11	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	11	suppressed
Victoza 3-Pak	Liraglutide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error